1-(benzyloxy)-3,5-difluoro-2-nitrobenzene | 256523-59-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(benzyloxy)-3,5-difluoro-2-nitrobenzene
• 英文别名: 2-Benzyloxy-4,6-difluoronitrobenzene；1,5-difluoro-2-nitro-3-phenylmethoxybenzene
• CAS: 256523-59-8
• 化学式: C₁₃H₉F₂NO₃
• 分子量: 265.216
• InChiKey: YOKPUTOXWQZWBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(benzyloxy)-3,5-difluoro-2-nitrobenzene 在 palladium on activated charcoal 、 10 wt% Pd(OH)2 on carbon 、 氨 、 氢气 、 铁粉 、 sodium hydride 、 氯化铵 、 溶剂黄146 、 1-丙基磷酸酐 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 60.0 ℃ 、310.27 kPa 条件下， 反应 36.0h， 生成 6-fluoro-2-(hydroxymethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-4-ol
  参考文献：
  名称：

  WO2020033784A5

  摘要：

  公开号：

  WO2020033784A5
• 作为产物：
  描述：

  2,4,6-三氟硝基苯 、 苯甲醇 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.5h， 以21.2 g的产率得到1-(benzyloxy)-3,5-difluoro-2-nitrobenzene
  参考文献：
  名称：

  WO2020033784A5

  摘要：

  公开号：

  WO2020033784A5

文献信息

• [EN] NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS<br/>[FR] NOUVEAUX DERIVES DE CYANOPYRIDINE UTILES DANS LE TRAITEMENT DU CANCER ET D'AUTRES TROUBLES
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2004078747A1

  公开（公告）日：2004-09-16

  This invention relates to novel diaryl ureas of Formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper­proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

  本发明涉及公式（I）的新型二芳基脲、包含这些化合物的药物组合物以及将这些化合物或组合物用于治疗增殖过度和血管生成障碍的方法，作为单一药物或与细胞毒性治疗联合使用。
• Vla-4 inhibitors
  申请人：——

  公开号：US20040110945A1

  公开（公告）日：2004-06-10

  The present invention relates to a compound represented by the following formula (I): 1 (wherein, W represents W A —A 1 —W B — (in which, W A is substituted or unsubstituted aryl, etc., A 1 is —NR 1 —, single bond, —C(O)—, etc., and W B is substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH 2 —, alkenylene, etc., X is —C(O)—, —CH 2 —, etc., and M is, for example, the following formula: 2 (in which, R 11 , R 12 and R 13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R 14 is hydrogen or lower alkyl, Y represents —CH 2 —O—, etc., Z is substituted or unsubstituted arylene, etc., A 2 is single bond, etc, and R 10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

  本发明涉及以下式(I)所表示的化合物：1（其中，W代表WA-A1-WB-（其中，WA是取代或未取代的芳基等，A1是-NR1-，单键，-C（O）-等，WB是取代或未取代的芳烃基等），R是单键，-NH-，-OCH2-，烯烃基等，X是-C（O）-，-CH2-等，M是例如以下公式：2（其中，R11，R12和R13分别独立地代表氢，羟基，氨基，卤素等，R14是氢或低级烷基，Y代表-CH2-O-等，Z是取代或未取代的芳烃基等，A2是单键等，而R10是羟基或低级烷氧基），或其盐；以及含有该化合物的药物。该化合物或其盐选择性地抑制细胞黏附分子与VAL-4的结合，并表现出高的生物利用度，因此可用作预防和/或治疗炎症性疾病、自身免疫性疾病、转移、支气管哮喘、鼻窦狭窄、糖尿病等。
• Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
  申请人：Dumas Jacques

  公开号：US20050038031A1

  公开（公告）日：2005-02-17

  This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

  本发明涉及新型二芳基脲、含有这些化合物的药物组合物以及使用这些化合物或组合物治疗过度增殖和血管生成障碍的方法，可以作为单一药物或与细胞毒性治疗联合使用。
• 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
  申请人：Barnes David

  公开号：US20100035942A1

  公开（公告）日：2010-02-11

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  式（I）的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，例如SH2结构域。因此，式（I）的化合物可用于预防和/或治疗与肥胖相关的胰岛素抵抗、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病，伴随2型糖尿病的疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors
  申请人：Novartis AG

  公开号：US08252820B2

  公开（公告）日：2012-08-28

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐量不良、糖尿病、高血压和大、小血管缺血性疾病有关的胰岛素抵抗症状。这些疾病包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他胰岛素抵抗症状。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。